ORGANIZATION AND NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)			1 Months Ended					3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 03, 2023	Jan. 06, 2023	Jan. 23, 2024	Jun. 30, 2023	Jun. 15, 2023	Apr. 24, 2023	Feb. 28, 2023	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Depreciation expense								$ 97,539	$ 103,558	$ 212,553	$ 216,432
Allowance for doubtful accounts								25,830,462		25,830,462		$ 22,799,219
Net receivable balance								574,985		574,985		534,263
Amortization expense								249,811	$ 193,518	458,644	$ 383,373
Other Liabilities								434,821		434,821		377,264
Building Acquision [Member]
Cash		$ 3,950,000				$ 1,054,872
Equity method investment aggregate cost								2,000,020		2,000,020
Pancreta Bank [Member]
Investments in debt and equity securities								$ 16,666		$ 16,666
Share Price								$ 1.08		$ 1.08
Recurring Fair Value										$ 18,049
Equity Securities										$ 7,665
Greece [Member]
Corporate income tax rate										22.00%
Cash					$ 109,330
Intangible assets					425,411
Issuable stock amount					$ 316,081
Shares issued					99,710
United Kingdom [Member]
Corporate income tax rate										25.00%
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]
Cash				$ 873,600
Issuable stock amount				$ 138,667								138,667
Shares issued				46,377
Asset acquision							$ 5,469,787
Secured Promissory Note							$ 4,457,520
Zip Doctor Inc [Member]
Cash	$ 150,000
Payment of fees	8,788
Intangible assets	$ 158,788
Impairment charge												$ 131,032
Cloudscreen [Member]
Cash			$ 317,880
Total purchase price amount			$ 637,080
Shares of common stock issued			280,000
Shares of common fair value			$ 319,200
Asset acquisition			$ 637,080